Nanoparticles in cancer therapy and diagnosis

Advanced Drug Delivery Reviews

Volumn 64, Issue SUPPL., 2012, Pages 24-36

  Brigger, Irène ^a   Dubernet, Catherine ^a   Couvreur, Patrick ^a  

^a UNIVERSITÉ PARIS SACLAY   (France)

Author keywords

Conventional or long circulating carriers; EPR effect; Multidrug resistance (MDR); Nanocapsules; Nanoparticles; Nanospheres; Oligonucleotide delivery; Passive or active tumor targeting; Tumor imaging

Indexed keywords

ANTI-TUMOR EFFICACY; ANTICANCER DRUG; CANCER DIAGNOSIS; CANCER THERAPY; CANCEROUS CELLS; CELL DISTRIBUTION; COLLOIDAL SYSTEM; EPR EFFECT; IN-VIVO; INTRAVASCULAR; MOLECULAR LIGANDS; MULTIDRUG RESISTANCE; SIDE EFFECT; TUMOR CELLS; TUMOR IMAGING; TUMOR REGRESSION; TUMOR TARGETING;

CHEMOTHERAPY; DRUG PRODUCTS; NANOCAPSULES; NANOPARTICLES; NANOSPHERES; OLIGONUCLEOTIDES; TUMORS;

DIAGNOSIS;

ACLARUBICIN; ANTINEOPLASTIC AGENT; ANTISENSE OLIGONUCLEOTIDE; CETRIMONIUM CHLORIDE; CHITOSAN; CYANOACRYLATE; CYANOACRYLATE DERIVATIVE; CYCLOSPORIN A; CYTOTOXIC AGENT; DOXORUBICIN; EPIRUBICIN; FERUMOXSIL; MACROGOL; MITOMYCIN C; MITOXANTRONE; MULTIDRUG RESISTANCE PROTEIN; NANOPARTICLE; PACLITAXEL; PHOSPHOROTHIOIC ACID DERIVATIVE; PHTHALOCYANINE ZINC; POLOXAMINE 908; POLY(ETHYL 2 CYANOACRYLATE); POLY(HEXYL 2 CYANOACRYLATE); POLY(METHYL METHACRYLATE); POLYCAPROLACTONE; POLYLACTIC ACID; POLYSACCHARIDE; SUPERPARAMAGNETIC IRON OXIDE; ULTRASMALL SUPERPARAMAGNETIC IRON OXIDE; UNINDEXED DRUG;

ANTINEOPLASTIC ACTIVITY; BLOOD TOXICITY; BONE MARROW SUPPRESSION; BREAST CANCER; CANCER DIAGNOSIS; CANCER THERAPY; CARDIOTOXICITY; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC IMAGING; DRUG ABSORPTION; DRUG COATING; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG RELEASE; DRUG TARGETING; DRUG TISSUE LEVEL; EWING SARCOMA; GENOTOXICITY; HUMAN; LIVER TOXICITY; LYMPH NODE METASTASIS; METASTASIS INHIBITION; MULTIDRUG RESISTANCE; NANOEMULSION; NANOENCAPSULATION; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RADIODIAGNOSIS; REVIEW; SOLID TUMOR; TUMOR CELL; TUMOR REGRESSION;

EID: 84870251926     PISSN: 0169409X     EISSN: 18728294     Source Type: Journal    
DOI: 10.1016/j.addr.2012.09.006     Document Type: Review

References (98)

1. Jain R.K. Transport of molecules in the tumor interstitium: a review. Cancer Res. 1987, 47:3039-3051.
2. Jain R.K. Delivery of molecular medicine to solid tumors: lessons from in vivo imaging of gene expression and function. J. Control. Release 2001, 74:7-25.
3. Seymour L.W. Passive tumor targeting of soluble macromolecules and drug conjugates. Crit. Rev. Ther. Drug Carrier Syst. 1992, 9:135-187.
4. Baban D., Seymour L.W. Control of tumor vascular permeability. Adv. Drug Deliv. Rev. 1998, 34:109-119.
5. Maeda H. The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting. Adv. Enzyme Regul. 2001, 41:189-207.
6. Hobbs S.K., Monsky W.L., Yuan F., Roberts W.G., Griffith L., Torchilin V.P., Jain R.K. Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment. Proc. Natl. Acad. Sci. USA 1998, 95:4607-4612.
7. Yuan F., Dellian M., Fukumura D., Leuning M., Berk D.D., Yorchilin V.P., Jain R.K. Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size. Cancer Res. 1995, 55:3752-3756.
8. Unezaki S., Maruyama K., Hosoda J.-I., Nagae I., Koyanagi Y., Nakata M., Ishida O., Iwatsuru M., Tsuchiya S. Direct measurement of the extravasation of polyethyleneglycol-coated liposomes into solid tumor tissue by in vivo fluorescence microscopy. Int. J. Pharm. 1996, 144:11-17.
9. Links M., Brown R. Clinical relevance of the molecular mechanisms of resistance to anti-cancer drugs. Expert Rev. Mol. Med. 1999, 1:1-21.
10. Krishna R., Mayer L.D. Multidrug resistance (MDR) in cancer-mechanisms, reversal using modulators of MDR and the role of MDR modulators in influencing the pharmacokinetics of anticancer drugs. Eur. J. Cancer Sci. 2000, 11:265-283.
11. Couvreur P., Couarraze G., Devissaguet J.-P., Puisieux F. Nanoparticles: preparation and characterization. Microencapsulation: Methods and Industrial Application 1996, 183-211. Marcel Dekker, New York. S. Benita (Ed.).
12. Yuan F. Transvascular drug delivery in solid tumors. Semin. Radiat. Oncol. 1998, 8:164-175.
13. Moghimi S.M., Hunter A.C., Murray J.C. Long-circulating and target-specific nanoparticles: theory to practice. Pharmacol. Rev. 2001, 53:283-318.
14. Noguchi Y., Wu J., Duncan R., Strohalm J., Ulbrich K., Akaike T., Maeda H. Early phase tumor accumulation of macromolecules: a great difference in clearance rate between tumor and normal tissues. Jpn. J. Cancer Res. 1998, 89:307-314.
15. Maeda H., Wu J., Sawa T., Matsumura Y., Hori K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J. Control. Release 2000, 65:271-284.
16. Grislain L., Couvreur P., Lenaerts V., Roland M., Deprez-Decampeneere D., Speiser P. Pharmacokinetics and distribution of a biodegradable drug-carrier. Int. J. Pharm. 1983, 15:335-345.
17. Verdun C., Brasseur F., Vranckx H., Couvreur P., Roland M. Tissue distribution of doxorubicin associated with polyhexylcyanoacrylate nanoparticles. Cancer Chemother. Pharmacol. 1990, 26:13-18.
18. Brasseur F., Couvreur P., Kante B., Deckers-Passau L., Roland M., Deckers C., Speiser P. Actinomycin D adsorbed on polymethylcyanoacrylate nanoparticles: increased efficiency against an experimental tumor. Eur. J. Cancer 1980, 10:1441-1445.
19. Couvreur P., Kante B., Lenaerts V., Scailteur V., Roland M., Speiser P. Tissue distribution of antitumor drugs associated with polyalkylcyanoacrylate nanoparticles. J. Pharm. Sci. 1980, 69:199-202.
20. Chiannilkulchai N., Driouich Z., Benoit J.P., Parodi A.L., Couvreur P. Doxorubicin-loaded nanoparticles: increased efficiency in murine hepatic metastasis. Sel. Cancer Ther. 1989, 5:1-11.
21. Chiannilkulchai N., Ammoury N., Caillou B., Devissaguet J.Ph., Couvreur P. Hepatic tissue distribution of doxorubicin-loaded particles after i.v. administration in reticulosarcoma M 5076 metastasis-bearing mice. Cancer Chemother. Pharmacol. 1990, 26:122-126.
22. Soma C.E., Dubernet C., Barratt G., Benita S., Couvreur P. Investigation of the role of macrophages on the cytotoxicity of doxorubicin and doxorubicin-loaded nanoparticles on M5076 cells in vitro. J. Control. Release 2000, 68:283-289.
23. Daemen T., Hofstede G., Kate M.T.T., Bakker-Woudenberg I.A.J.M., Scherphof G. Liposomal doxorubicin-induced toxicity: depletion and impairment of phagocytic activity of liver macrophages. Int. J. Cancer 1995, 61:716-721.
24. Gibaud S., Andreux J.P., Weingarten C., Renard M., Couvreur P. Increased bone marrow toxicity of doxorubicin bound to nanoparticles. Eur. J. Cancer A 1994, 30:820-826.
25. Manil L., Couvreur P., Mahieu P. Acute renal toxicity of doxorubicin (adriamycin)-loaded cyanoacrylate nanoparticles. Pharm. Res. 1995, 12:85-87.
26. Couvreur P., Kante B., Grislain L., Roland M., Speiser P. Toxicity of polyalkylcyanoacrylate nanoparticles II: doxorubicin-loaded nanoparticles. J. Pharm. Sci. 1982, 71:790-792.
27. Blagoeva P.M., Balansky R.M., Mircheva T.J., Simeonova M.I. Diminished genotoxicity of mitomycin C and farmorubicin included in polybutylcyanoacrylate nanoparticles. Mutat. Res. 1992, 268:77-82.
28. Rolland A. Clinical pharmacokinetics of doxorubicin in hepatoma patients after a single intravenous injection of free or nanoparticle-bound anthracycline. Int. J. Pharm. 1989, 54:113-121.
29. Kattan J., Droz J.P., Couvreur P., Marino J.P., Boutan-Laroze A., Rougier P., Brault P., Vranckx H., Grognet J.-M., Morge X., Sancho-Garnier H. Phase I clinical trial and pharmacokinetics evaluation of doxorubicin carried by polyisohexylcyanoacrylate nanoparticles. Invest. New Drugs 1992, 10:191-199.
30. Storm G., Belliot S.O., Daemen T., Lasic D.D. Surface modification of nanoparticles to oppose uptake by the mononuclear phagocyte system. Adv. Drug Deliv. Rev. 1995, 17:31-48.
31. Stolnik S., Illum L., Davis S.S. Long circulating microparticulate drug carriers. Adv. Drug Deliv. Rev. 1995, 16:195-214.
32. Gref R., Minamitake Y., Peracchia M.T., Trubetskoy V., Torchilin V., Langer R. Biodegradable long-circulating polymeric nanospheres. Science 1994, 263:1600-1603.
33. Sharma D., Chelvi T.P., Kaur J., Chakravorty K., De T.K., Maitra A., Ralhan R. Novel taxol® formulation: polyvinylpyrrolidone nanoparticles-encapsulated taxol® for drug delivery in cancer therapy. Oncol. Res. 1996, 8:281-286.
34. Mitra S., Gaur U., Gosh P.C., Maitra A.N. Tumor targeted delivery of encapsulated dextran-doxorubicin conjugate using chitosan nanoparticles as carrier. J. Control. Release 2001, 74:317-323.
35. Torchilin V.P., Trubetskoy V.S. Which polymer can make nanoparticulate drug carriers long-circulating?. Adv. Drug Deliv. Rev. 1995, 16:141-155.
36. Jeon S.I., Lee J.H., Andrade J.D., de Gennes P.G. Protein-surface interactions in the presence of polyethylene oxide. I. Simplified theory. J. Colloid Interface Sci. 1991, 142:149-158.
37. Jeon S.I., Andrade J.D. Protein-surface interactions in the presence of polyethylene oxide. II. Effect of protein size. J. Colloid Interface Sci. 1991, 142:159-166.
38. Reszka R., Beck P., Fichtner I., Hentschel M., Richter L., Kreuter J. Body distribution of free, liposomal and nanoparticle-associated mitoxantrone in B16-melanoma-bearing mice. J. Pharmacol. Exp. Ther. 1997, 280:232-237.
39. Gulyaev A.E., Gelperina S.E., Skidan I.N., Antropov A.S., Kivman G.Y., Kreuter J. Significant transport of doxorubicin into the brain with polysorbate 80-coated nanoparticles. Pharm. Res. 1999, 16:1564-1569.
40. Kreuter J. Nanoparticulate systems for brain delivery of drugs. Adv. Drug. Deliv. Rev. 2000, 47:65-81.
41. Gelperina S.E., Smirnova Z.S., Khalanskiy A.S., Skidan I.N., Bobruskin A.I., Kreuter J. Chemotherapy of brain tumours using doxorubicin bound to polysorbate 80-coated nanoparticles. Proceedings of the 3rd World Meeting APV/APGI, Berlin, April 2000, 441-442.
42. 14C-poly(methylmethacrylate) nanoparticles in experimental tumor models. Pharm. Res. 2001, 18:1613-1619.
43. Bazile D., Prud'homme C., Bassoulet M.-T., Marlard M., Spenlehauer G., Veillard M. Stealth Me.PEG-PLA nanoparticles avoid uptake by the mononuclear phagocyte system. J. Pharm. Sci. 1995, 84:493-498.
44. Peracchia M.T., Vauthier C., Puisieux F., Couvreur P. Development of sterically stabilized poly(isobutyl 2-cyanoacrylate) nanoparticles by chemical coupling of poly(ethylene glycol). J. Biomed. Mater. Res. 1997, 34:317-326.
45. Peracchia M.T., Vauthier C., Desmaële D., Gulik A., Dedieu J.-C., Demoy M., d'Angelo J., Couvreur P. Pegylated nanoparticles from a novel methoxypolyethylene glycol cyanoacrylate-hexadecyl cyanoacrylate amphiphilic copolymer. Pharm. Res. 1998, 15:550-556.
46. Allémann E., Rousseau J., Brasseur N., Kudrevich S.V., Lewis K., van Lier J.E. Photodynamic therapy of tumours with hexadecafluoro zinc phthalocyanine formulated in PEG-coated poly(lactic acid) nanoparticles. Int. J. Cancer 1996, 66:821-824.
47. Hawley A.E., Davis S.S., Illum L. Targeting of colloids to lymph nodes: influence of lymphatic physiology and colloidal characteristics. Adv. Drug. Deliv. Rev. 1995, 17:129-148.
48. Nishioka Y., Yoshino H. Lymphatic targeting with nanoparticulate system. Adv. Drug Deliv. Rev. 2001, 47:55-64.
49. Sakakura C., Takahashi T., Sawai K., Hagiwara A., Ito M., Shobayashi S., Sasaki S., Ozaki K., Shirasu M. Enhancement of therapeutic efficacy of aclarubicin against lymph node metastases using a new dosage form: aclarubicin adsorbed on activated carbon particles. Anti-Cancer Drugs 1992, 3:233-236.
50. Hagiwara A., Takahashi T., Sawai K., Sakakura C., Shirasu M., Ohgaki M., Imanashi T., Yamasaki J., Takemoto Y., Kageyama N. Selective drug delivery to peri-tumoral region and regional lymphatics by local injection of aclarubicin adsorbed on activated carbon particles in patients with breast cancer-a pilot study. Anti-Cancer Drugs 1997, 8:666-670.
51. Tokumitsu H., Hiratsuka J., Sakurai Y., Kobayashi T., Ichikawa H., Fukumori Y. Gadolinium neutron-capture therapy using novel gadopentetic acid-chitosan complex nanoparticles: in vivo growth suppression of experimental melanoma solid tumor. Cancer Lett. 2000, 150:177-182.
52. Juliano R.L., Alahari S., Yoo H., Kole R., Cho M. Antisense pharmacodynamics: critical issues in the transport and delivery of antisense oligonucleotides. Pharm. Res. 1999, 16:494-502.
53. Fattal E., Vauthier C., Aynié I., Nakada Y., Lambert G., Malvy C., Couvreur P. Biodegradable polyalkylcyanoacrylate nanoparticles for the delivery of oligonucleotides. J. Control. Release 1998, 53:137-143.
54. Aynié I., Vauthier C., Chacun H., Fattal E., Couvreur P. Sponge-like alginate nanoparticles as a new potential system for the delivery of antisense oligonucleotides. Antisense Nucleic Acid Drug Dev. 1999, 9:301-312.
55. Lambert G., Fattal E., Pinto-Alphandary H., Gulik A., Couvreur P. Polyisobutylcyanoacrylate nanocapsules containing an aqueous core as a novel colloidal carrier for the delivery of oligonucleotides. Pharm. Res. 2000, 17:707-714.
56. Schwab G., Chavany C., Duroux I., Goubin G., Lebeau J., Hélène C., Saison-Behmoaras T. Antisense oligonucleotides adsorbed to polyalkylcyanoacrylate nanoparticles specifically inhibit mutated Ha-ras-mediated cell proliferation and tumorigenicity in nude mice. Proc. Natl. Acad. Sci. USA 1994, 91:10460-10464.
57. Chavany C., Saison-Behmoaras T., Le Doan T., Puisieux F., Couvreur P., Hélène C. Adsorption of oligonucleotides onto poly(isohexylcyanoacrylate) nanoparticles protects them against nucleases and increases their cellular uptake. Pharm. Res. 1994, 11:1370-1378.
58. Godard G., Boutorine A.S., Saison-Behmoaras E., Hélène C. Antisense effect of cholesterol-oligodeoxynucleotide conjugates associated with poly(alkylcyanoacrylate) nanoparticles. Eur. J. Biochem. 1995, 232:404-410.
59. Tondelli L., Ricca A., Laus M., Lelli M., Citro G. Highly efficient cellular uptake of c-myb antisense oligonucleotides through specifically designed polymeric nanospheres. Nucleic Acids Res. 1998, 26:5425-5431.
60. Zimmer A. Antisense oligonucleotide delivery with polyhexylcyanoacrylate nanoparticles as carriers. Methods: A Companion to Methods in Enzymology 1999, 18:286-295.
61. Ganachaud F., Elaissari A., Pichot C., Laayoun A., Cros P. Adsorption of single-strand DNA fragments onto cationic aminated latex particles. Langmuir 1997, 13:701-707.
62. Lambert G., Bertrand J.R., Fattal E., Subra F., Pinto-Alphandary H., Malvy C., Auclair C., Couvreur P. EWS Fli-1 antisense nanocapsules inhibits Ewing sarcoma-related tumor in mice. Biochem. Biophys. Res. Commun. 2000, 279:401-406.
63. Tanaka K., Iwakuma T., Harimaya K., Sato H., Iwamoto Y. EWS-Fli1 antisense oligodeoxynucleotide inhibits proliferation of human Ewing's sarcoma and primitive neuroectodermal tumor cells. J. Clin. Invest. 1997, 99:239-247.
64. Larsen A.K., Escargueil A.E., Skladanowski A. Resistance mechanisms associated with altered intracellular distribution of anticancer agents. Pharmacol. Ther. 2000, 88:217-229.
65. Bennis S., Chapey C., Couvreur P., Robert J. Enhanced cytotoxicity of doxorubicin encapsulated in polyhexylcyanoacrylate nanospheres against multi-drug-resistant tumour cells in culture. Eur. J. Cancer A 1994, 30:89-93.
66. Hu Y.-P., Jarillon S., Dubernet C., Couvreur P., Robert J. On the mechanism of action of doxorubicin encapsulation in nanospheres for the reversal of multidrug resistance. Cancer Chemother. Pharmacol. 1996, 37:556-560.
67. Colin de Verdière A., Dubernet C., Némati F., Poupon M.F., Puisieux F., Couvreur P. Uptake of doxorubicin from loaded nanoparticles in multidrug-resistant leukemic murine cells. Cancer Chemother. Pharmacol. 1994, 33:504-508.
68. Cuvier C., Roblot-Treupel L., Millot J.M., Lizard G., Chevillard S., Manfait M., Couvreur P., Poupon M.F. Doxorubicin-loaded nanospheres bypass tumor cell multidrug resistance. Biochem. Pharmacol. 1992, 44:509-517.
69. Colin de Verdière A., Dubernet C., Némati F., Soma E., Appel M., Ferté J., Bernard S., Puisieux F., Couvreur P. Reversion of multidrug resistance with polyalkylcyanoacrylate nanoparticles: towards a mechanism of action. Br. J. Cancer 1997, 76:198-205.
70. Pépin X., Attali L., Domrault C., Gallet S., Metreau J.M., Reault Y., Cardot P.J.P., Imalalem M., Dubernet C., Soma E., Couvreur P. On the use of ion-pair chromatography to elucidate doxorubicin release mechanism from polyalkylcyanoacrylate nanoparticles at the cellular level. J. Chromatogr. B 1997, 702:181-197.
71. Astier A., Doat B., Ferrer M.-J., Benoit G., Fleury J., Rolland A., Leverge R. Enhancement of adriamycin antitumor activity by its binding with an intracellular sustained-release form, polymethacrylate nanospheres, in U-937 cells. Cancer Res. 1988, 48:1835-1841.
72. Nafziger J., Averland G., Bertounesque E., Gaudel G., Monneret C. Synthesis and antiproliferative effects of a 4'-morpholino-9-methyl anthracycline. J. Antibiot. 1995, 48:1185-1187.
73. Yokoyama M., Okano T., Sakurai Y., Fukushima S., Okamoto K., Kataoka K. Selective delivery of adriamycin to a solid tumor using a polymeric micelle carrier system. J. Drug Target. 1999, 7:171-186.
74. Leo E., Arletti R., Forni F., Cameroni R. General and cardiac toxicity of doxorubicin-loaded gelatin nanoparticles. Il Farmaco 1997, 52:385-388.
75. Kubiak C., Couvreur P., Manil L., Clausse B. Increased cytotoxicity of nanoparticle-carried adriamycin in vitro and potentiation by verapamil and amiodarone. Biomaterials 1989, 10:553-556.
76. Soma C.E., Dubernet C., Bentolila D., Benita S., Couvreur P. Reversion of multidrug resistance by co-encapsulation of doxorubicin and cyclosporin A in polyalkylcyanoacrylate nanoparticles. Biomaterials 2000, 21:1-7.
77. Müller R.H., Lherm C., Herbort J., Couvreur P. In vitro model for the degradation of alkylcyanoacrylate nanoparticles. Biomaterials 1990, 11:590-595.
78. Stella B., Arpicco S., Peracchia M.T., Desmaële D., Hoebeke J., Renoir M., d'Angelo J., Cattel L., Couvreur P. Design of folic acid-conjugated nanoparticles for drug targeting. J. Pharm. Sci. 2000, 89:1452-1464.
79. Stella B., Marsaud V., Couvreur P., Arpicco S., Peracchia M.T., Geraud G., Immordino M.L., Cattel L., Renoir M. Biological characterisation of folic acid-conjugated nanoparticles in cellular models. Proceedings of the Controlled Release of Bioactive Materials Congress, San Diego 2001, No. 5200.
80. Bhalgat M.K., Haugland R.P., Pollack J.S., Swan S., Haugland R.P. Green- and red-fluorescent nanospheres for the detection of cell surface receptors by flow cytometry. J. Immunol. Methods 1998, 219:57-68.
81. Väisänen V., Härmä H., Lilja H., Bjartell A. Time-resolved fluorescence imaging for quantitative histochemistry using lanthanide chelates in nanoparticles and conjugated to monoclonal antibodies. Luminescence 2000, 15:389-397.
82. Santra S., Wang K., Tan R.T.W. Development of novel dye-doped silica nanoparticles for biomarker application. J. Biomed. Opt. 2001, 6:160-166.
83. Davis S.S., Frier M., Illum L. Colloidal particles as radiodiagnostic agents. Polymeric Nanoparticles and Microspheres 1986, 175-197. CRC Press, Boca Raton, FL. P. Guiot, P. Couvreur (Eds.).
84. Ghanem G.E., Joubran C., Arnould R., Lejeune F., Fruhling J. Labelled polycyanoacrylate nanoparticles for human in vivo. Appl. Radiat. Isot. 1993, 44:1219-1224.
85. Wisner E.R., Katzberg R.W., Link D.P., Griffey S.M., Drake C.M., Vessey A.R., Johnson D., Haley P.J. Indirected computed tomography lymphography using iodinated nanoparticles to detect cancerous lymph nodes in a cutaneous melanoma model. Acad. Radiol. 1996, 3:40-48.
86. Wisner E.R., Katzberg R.W., Griffey S.M., Haley P.J., Johnson D.K., Vessey A.R. Characterization of normal and cancerous lymph nodes on indirect computed tomography lymphographic studies after interstitial injection of iodinated nanoparticles. Acad. Radiol. 1996, 3:S257-S260.
87. Bonnemain B. Superparamagnetic agents in magnetic resonance imaging: physicochemical characteristics and clinical applications-a review. J. Drug Target. 1998, 6:167-174.
88. Moore A., Marecos E., Bogdanov A., Weissleder R. Tumoral distribution of long-circulating dextran-coated iron oxide nanoparticles in a rodent model. Radiology 2000, 214:568-574.
89. Zimmer C., Weissleder R., Poss K., Bogdanova A., Wright S.C., Enochs W.S. MR imaging of phagocytosis in experimental glioma. Radiology 1995, 197:533-538.
90. Moore A., Weissleder R., Bogdanov A. Uptake of dextran-coated monocrystalline iron oxides in tumor cells and macrophages. J. Magn. Reson. Imaging 1997, 7:1140-1145.
91. Enochs W.S., Harsh G., Hochberg F., Weissleder R. Improved delineation of human brain tumors on MR images using long-circulating, superparamagnetic iron oxide agent. J. Magn. Reson. Imaging 1999, 9:228-232.
92. Weissleder R., Heautot J.F., Schaffer B.K., Nossiff N., Papisov M.I., Bogdanov A., Brady T.J. MR lymphography: study of a high-efficiency lymphotrophic agent. Radiology 1994, 191:225-230.
93. Clément O., Guimaraes R., de Kerviler E., Frija G. Magnetic resonance lymphography-Enhancement patterns using superparamagnetic nanoparticles. Invest. Radiol. 1994, 29:S226-S228.
94. Högemann D., Josephson L., Weissleder R., Basilion J.P. Improvement of MRI probes to allow efficient detection of gene expression. Bioconjug. Chem. 2000, 11:941-946.
95. Tiefenauer L.X., Kühne G., Andres R.Y. Antibody-magnetite nanoparticles: in vitro characterization of a potential tumor-specific contrast agent for magnetite resonance imaging. Bioconjug. Chem. 1993, 4:347-352.
96. Kirsh M., Strasser J., Allende R., Bello L., Zhang J., Black P. Angiostatin suppresses malignant glioma growth in vivo. Cancer Res. 1998, 58:4654-4659.
97. Li Y.-P., Pei Y.-Y., Zhou Z.-H., Zhang X.-Y., Gu Z.-H., Ding J., Zhou J.-J., Gao X.-J. Pegylated polycyanoacrylate nanoparticles as tumor necrosis-α carriers. J. Control. Release 2001, 71:287-296.
98. Yoo H.S., Lee K.H., Oh J.E., Park T.G. In vitro and in vivo anti-tumor activities of nanoparticles based on doxorubicin-PLGA conjugate. J. Control. Release 2000, 68:419-431.